Brain-Computer Interface Company Synchron Raises $200M
Synchron, a New York-based developer of non-surgical brain-computer interface (BCI) technology, has secured $200 million in a Series D funding round. This investment will fast-track the commercialization of the company’s first-generation Stentrode BCI platform and support the development of its next-generation interface.
Funding Details and Investors
- The Series D round was led by Double Point Ventures.
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New participants are the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
- With this round, Synchron’s total funding reaches $345 million.
Stentrode BCI Platform
The Stentrode is the first endovascular brain-computer interface designed to convert brain activity into digital commands without the need for open-brain surgery. It is implanted through a non-surgical catheter procedure into the motor cortex via blood vessels.
Synchron said the device records and transmits neural signals wirelessly, empowering users to control digital devices hands-free.
Advancing Brain-Computer Technology
Along with commercializing the current platform, the raised funds will accelerate the creation of a next-generation interface aimed at expanding the capabilities of brain-computer communication.
Summary: Synchron’s major investment will drive the widespread use of their groundbreaking, minimally invasive brain-computer interface and fuel new technological advancements in neural control systems.